ASX - By Stock
|
MSB |
Re:
Entering the PAZ - give us your predictions!
|
|
Pharmagang
|
166 |
56K |
87 |
12/09/24 |
12/09/24 |
ASX - By Stock
|
166
|
56K
|
87
|
|
ASX - By Stock
|
MSB |
Re:
Entering the PAZ - give us your predictions!
|
|
Pharmagang
|
166 |
56K |
117 |
11/09/24 |
11/09/24 |
ASX - By Stock
|
166
|
56K
|
117
|
|
ASX - By Stock
|
MSB |
Re:
June 24 - MSB % of portfolio AND + or - %
|
|
Pharmagang
|
88 |
35K |
60 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
88
|
35K
|
60
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Pharmagang
|
236 |
98K |
90 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
236
|
98K
|
90
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Pharmagang
|
226 |
84K |
6 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
84K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Pharmagang
|
226 |
84K |
24 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
84K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Pharmagang
|
549 |
186K |
24 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
549
|
186K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Pharmagang
|
549 |
186K |
85 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
186K
|
85
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Pharmagang
|
18K |
7.0M |
16 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
18K
|
7.0M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Pharmagang
|
18K |
7.0M |
20 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
18K
|
7.0M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Pharmagang
|
18K |
7.0M |
76 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
18K
|
7.0M
|
76
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Pharmagang
|
913 |
297K |
66 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
913
|
297K
|
66
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Pharmagang
|
3.4K |
1.2M |
190 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
3.4K
|
1.2M
|
190
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Pharmagang
|
11K |
3.4M |
56 |
18/11/22 |
18/11/22 |
ASX - By Stock
|
11K
|
3.4M
|
56
|
|
ASX - By Stock
|
MSB |
Re:
RWE for 2nd MSB COVID-19 ARDS P3 Trial
|
|
Pharmagang
|
905 |
294K |
16 |
18/02/22 |
18/02/22 |
ASX - By Stock
|
905
|
294K
|
16
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
26 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Pharmagang
|
18K |
7.0M |
22 |
13/12/21 |
13/12/21 |
ASX - By Stock
|
18K
|
7.0M
|
22
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
61 |
12/12/21 |
12/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
61
|
|
ASX - General
|
|
Re:
how do you post gifs?
|
|
Pharmagang
|
24 |
9.2K |
0 |
12/12/21 |
12/12/21 |
ASX - General
|
24
|
9.2K
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
85 |
11/12/21 |
11/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
85
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
1 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
|
|
Pharmagang
|
304 |
97K |
48 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
304
|
97K
|
48
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
|
|
Pharmagang
|
304 |
97K |
25 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
304
|
97K
|
25
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
24 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
10K
|
3.0M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Pharmagang
|
1.0K |
282K |
16 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
1.0K
|
282K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Pharmagang
|
1.0K |
282K |
147 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
1.0K
|
282K
|
147
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
49 |
05/11/21 |
05/11/21 |
ASX - By Stock
|
10K
|
3.0M
|
49
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
73 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
10K
|
3.0M
|
73
|
|
ASX - By Stock
|
MSB |
Re:
If Remestemcel-L is approved -kids srAGvHD
|
|
Pharmagang
|
24 |
11K |
36 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
24
|
11K
|
36
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
115 |
06/09/21 |
06/09/21 |
ASX - By Stock
|
10K
|
3.0M
|
115
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
119 |
02/09/21 |
02/09/21 |
ASX - By Stock
|
10K
|
3.0M
|
119
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Pharmagang
|
18K |
7.0M |
54 |
13/08/21 |
13/08/21 |
ASX - By Stock
|
18K
|
7.0M
|
54
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
73 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
10K
|
3.0M
|
73
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on Chronic Low Back Pain Program
|
|
Pharmagang
|
340 |
115K |
21 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
340
|
115K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on Chronic Low Back Pain Program
|
|
Pharmagang
|
340 |
115K |
36 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
340
|
115K
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on Chronic Low Back Pain Program
|
|
Pharmagang
|
340 |
115K |
66 |
01/07/21 |
01/07/21 |
ASX - By Stock
|
340
|
115K
|
66
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
56 |
25/06/21 |
25/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
56
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
110 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
10K
|
3.0M
|
110
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
113 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
10K
|
3.0M
|
113
|
|
ASX - By Stock
|
MSB |
Re:
News: MSB Mesoblast Ltd Files For Shelf Of Up To $180 Mln ADS Representing Ordinary Shares
|
|
Pharmagang
|
110 |
38K |
71 |
08/04/21 |
08/04/21 |
ASX - By Stock
|
110
|
38K
|
71
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
56 |
01/04/21 |
01/04/21 |
ASX - By Stock
|
10K
|
3.0M
|
56
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Operational Highlights and Upcoming Milestones
|
|
Pharmagang
|
177 |
57K |
37 |
31/03/21 |
31/03/21 |
ASX - By Stock
|
177
|
57K
|
37
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
58 |
31/03/21 |
31/03/21 |
ASX - By Stock
|
10K
|
3.0M
|
58
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
69 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
10K
|
3.0M
|
69
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Pharmagang
|
10K |
3.0M |
67 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
10K
|
3.0M
|
67
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
Pharmagang
|
1.1K |
319K |
75 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
319K
|
75
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
Pharmagang
|
1.1K |
319K |
13 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
319K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
Pharmagang
|
1.1K |
319K |
33 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
319K
|
33
|
|
ASX - By Stock
|
MSB |
Re:
MSB Vs PNV who will gain the most in 2020?
|
|
Pharmagang
|
97 |
249K |
1 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
97
|
249K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
Pharmagang
|
93 |
35K |
73 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
93
|
35K
|
73
|
|